Educational program will provide science-based information on extracellular vesicle science, secretome research and investigational biologic approaches in ARDS
AUSTIN, Texas – Sept. 15, 2026 – PRLog — Direct Biologics, LLC will serve as an Educational Sponsor of an upcoming educational webinar produced by ARDS Alliance, Inc. focused on Acute Respiratory Distress Syndrome, Extracellular Vesicle science, secretome research and investigational biologic approaches.
Supported through an educational grant from Direct Biologics, the webinar is being independently developed and produced by ARDS Alliance. The program is intended to provide patients, caregivers and other members of the ARDS community with accurate, science-based educational information and to help address common misconceptions surrounding investigational approaches, including their regulatory status.
The educational program will feature an independent physician or researcher as well as a patient perspective highlighting the experience and impact of ARDS. ARDS Alliance will independently select the speakers and maintain sole editorial control over the webinar and its educational content.
“The importance of independent, science-based education for patients and families, and our appreciation for the educational support that makes these programs possible, cannot be overstated,”
“ARDS is a complex and serious condition, and access to credible, understandable scientific information is important for patients and families navigating it,” said Tim Moseley PhD, CSO of Direct Biologics. “We are pleased to support ARDS Alliance in its efforts to provide independent education to the ARDS community.”
Direct Biologics’ sponsorship is limited to financial support of the educational program and does not provide the company with editorial control over the webinar. Sponsorship does not constitute an endorsement by ARDS Alliance of Direct Biologics, its products or any specific therapy.
The webinar is expected to take place later this year with the recording available through ARDS Alliance and Direct Biologics.
View the full press release here